Please assess the completion status of the following clinical trial:

Trial Title: RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Histopathologically proven, clinically stage II-III (cTNM according to AJCC/UICC classification), primary squamous cell carcinoma of the thoracic esophagus~* Patients' age above 18 years~* General condition with Karnofsky performance status of \>70~* Circulatory and pulmonary capacity at normal range (FEV1 \>60%; FVC \>60%, NYHA I-II, cardiac output \>40%)~* Normal function of the bone marrow (RBC \>3,5 T/l; PLT \>100 G/l)~* Normal renal (creatinine \<1.5 of the upper limit) and liver (AST or ALT \<2,5 of the upper limit or bilirubin \<1,5 of the upper limit) function~Exclusion Criteria:~* Metastatic disease~* Synchronous malignancy~* History of other cancer within 5 years prior to esophageal cancer treatment~* History of allergic reaction to cisplatin of 5-fluorouracil~* Systemic infection~* Pregnancy or female patients in childbearing age without proper contraceptives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- S (Type: ACTIVE_COMPARATOR): esophagectomy
- CHTS (Type: EXPERIMENTAL): neoadjuvant chemotherapy followed by esophagectomy
- CHRTS (Type: EXPERIMENTAL): neoadjuvant chemoradiotherapy followed by esophagectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).